Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences director Samit Hirawat received new equity awards. He was granted 6,405 restricted stock units of common stock, which will vest on June 10, 2027 if he remains in continuous service with the company through that date.
He was also granted stock options covering 10,891 shares of common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, and expire on June 10, 2036. Following these awards, he holds 6,405 common shares and options on 10,891 shares directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock in an open-market transaction at $23.50 per share. After the sale, she directly held 62,284.242 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
Pacira BioSciences director Christopher Christie received new equity compensation awards. He was granted 6,405 restricted stock units that vest on June 10, 2027, as long as he remains in continuous service with the company through that date. Each unit represents one share of common stock. He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share, which vests and becomes exercisable on June 10, 2027 and expires on June 10, 2036. Following these awards, Christie directly holds 23,059 shares of Pacira common stock. These are compensation-related grants, not open-market purchases or sales.
Pacira BioSciences director Thomas G. Wiggans received a stock option grant for 32,675 shares of common stock. The option has an exercise price of $23.42 per share and expires on June 10, 2036. One-third of the option vests on the first anniversary of the grant, with the remaining shares vesting in equal monthly installments over the following two years, as long as he remains in continuous service. After this grant, he holds options for 32,675 shares.
Pacira BioSciences director Alethia Young reported receiving equity compensation. On June 10, 2026, she was granted 6,405 restricted stock units, each representing one future share of common stock, and 10,891 stock options with an exercise price of $23.42 per share.
Both the restricted stock units and options vest on June 10, 2027, provided she remains in continuous service with Pacira through that date. Following the grant, she directly holds 17,798 shares of common stock, plus the newly granted options for 10,891 additional shares.
Pacira BioSciences director Michael J. Yang received new equity awards as part of his compensation. On June 10, 2026, he was granted 6,405 restricted stock units that will vest on June 10, 2027, if he remains in continuous service. Each unit converts into one share of common stock at vesting.
He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share. This option becomes exercisable on June 10, 2027, subject to the same service requirement, and expires on June 10, 2036. Following these awards, he directly holds 19,798 shares of common stock.
Pacira BioSciences director Marcelo Bigal received new equity awards as part of compensation. He was granted 6,405 restricted stock units, each representing one share of common stock, which vest on June 10, 2027 if he remains in continuous service with the company.
He also received a stock option covering 10,891 shares of common stock at an exercise price of $23.42 per share. This option vests on June 10, 2027 under the same service condition and expires on June 10, 2036. Following the grant, his direct holdings of common stock total 17,798 shares.
Pacira BioSciences director Mark Froimson received equity compensation consisting of restricted stock units and stock options. He was granted 6,405 restricted stock units, each representing the right to receive one share of Pacira common stock. These units vest on June 10, 2027, if he remains in continuous service through that date, and will then convert into common shares.
He was also granted 10,891 stock options to buy Pacira common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, subject to the same continuous service condition, and expire on June 10, 2036. Following the grant, Froimson directly holds 26,541 shares of Pacira common stock.
Pacira BioSciences director Laura Brege reported equity awards consisting of restricted stock units and stock options. She received 6,405 shares of common stock as a grant, bringing her directly held common shares to 30,120. She was also granted options for 10,891 shares at an exercise price of $23.42 per share.
The 6,405 restricted stock units vest on June 10, 2027, if she remains in continuous service with Pacira through that date. The stock options also vest on June 10, 2027 under the same service condition and will expire on June 10, 2036 if not exercised.
Pacira BioSciences, Inc. director Thomas G. Wiggans filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing shows no reported transactions, with zero shares listed as bought, sold, acquired, or disposed in the transaction summary.